Hutchison China MediTech Ltd ("Chi-Med"):
Chi-Med's pipeline has eight novel late stage oncology candidates with six Phase 3 trials and 20+ Phase 1b/2 trials currently underway that are fueled by its profitable Chinese commercial platform. Fruquintinib (VEGFR inhibitor, LLY-partnered) for colorectal cancer was approved in China in September 2018 and Phase 3 topline results in NSCLC is expected in late 2018. Savolitinib (C-Met inhibitor, AZN-partnered) for papillary renal cell carcinoma initiated a global Phase 3 trial in June 2017. AZN has the decision on strategy for Phase 3 registration and potential Breakthrough Therapy in NSCLC in combination with Tagrisso. Epitinib (1st-gen EGFR TKI) expects to initiate China Phase III study in 1L EGFRm NSCLC w/ brain mets in H2 2018. HMPL-523 (Syk inhibitor) preliminary safety and efficacy data from Phase I dose escalation studies in hematological cancer is expected in H2 2018.
Marketed, Phase III, Phase l or ll
Anti-inflammatory, Autoimmune, Immunotherapy, Oncology
230 Park Ave
New York, NY 10169
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.
Stock Market Data
Market Data copyright © 2017 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by